Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden

Roberto H. Nussenzveig, Ha T. Pham, Sherrie L. Perkins, Josef T. Prchal, Archana M. Agarwal, Mohamed Salama

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The frequency of co-existing JAK2V617F/MPL and JAK2V617F/JAK2 exon-12 mutations has not been previously investigated in MPNs. Poor survival was reported in primary myelofibrosis with low JAK2V617F allelic burden. However, mutational status of JAK2 exon-12 or MPL were not reported in these patients. This study developed a cost-effective multiplex high resolution melt assay that screens for mutations in JAK2 gene exons-12 and -14 (V617F) and MPL gene exon-10. Co-existing mutations with JAK2V617F were detected in 2.9% (6/208; two JAK2 exon-12 and four MPL exon-10) patient specimens with known JAK2V617F (allelic-burden range: 0.1-96.8%). Co-existing mutations were detected in specimens with < 12% JAK2V617F allelic burden. Current WHO guidelines do not recommend further testing once JAK2V617F mutation is detected in MPNs. The findings, however, indicate that quantification of JAK2V617F allele burden may be clinically relevant in MPNs and in those with low allelic burden additional testing for JAK2 exon-12 and MPL exon-10 mutation should be pursued.

Original languageEnglish (US)
Pages (from-to)1429-1435
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number6
DOIs
StatePublished - Jun 2 2016
Externally publishedYes

Fingerprint

Exons
Mutation
Primary Myelofibrosis
Genes
Alleles
Guidelines
Costs and Cost Analysis
Survival

Keywords

  • allelic burden
  • Co-existing mutations
  • myeloproliferative neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden. / Nussenzveig, Roberto H.; Pham, Ha T.; Perkins, Sherrie L.; Prchal, Josef T.; Agarwal, Archana M.; Salama, Mohamed.

In: Leukemia and Lymphoma, Vol. 57, No. 6, 02.06.2016, p. 1429-1435.

Research output: Contribution to journalArticle

Nussenzveig, Roberto H. ; Pham, Ha T. ; Perkins, Sherrie L. ; Prchal, Josef T. ; Agarwal, Archana M. ; Salama, Mohamed. / Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 6. pp. 1429-1435.
@article{54e2f60c0ba54536a69e403a1def08fd,
title = "Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden",
abstract = "The frequency of co-existing JAK2V617F/MPL and JAK2V617F/JAK2 exon-12 mutations has not been previously investigated in MPNs. Poor survival was reported in primary myelofibrosis with low JAK2V617F allelic burden. However, mutational status of JAK2 exon-12 or MPL were not reported in these patients. This study developed a cost-effective multiplex high resolution melt assay that screens for mutations in JAK2 gene exons-12 and -14 (V617F) and MPL gene exon-10. Co-existing mutations with JAK2V617F were detected in 2.9{\%} (6/208; two JAK2 exon-12 and four MPL exon-10) patient specimens with known JAK2V617F (allelic-burden range: 0.1-96.8{\%}). Co-existing mutations were detected in specimens with < 12{\%} JAK2V617F allelic burden. Current WHO guidelines do not recommend further testing once JAK2V617F mutation is detected in MPNs. The findings, however, indicate that quantification of JAK2V617F allele burden may be clinically relevant in MPNs and in those with low allelic burden additional testing for JAK2 exon-12 and MPL exon-10 mutation should be pursued.",
keywords = "allelic burden, Co-existing mutations, myeloproliferative neoplasms",
author = "Nussenzveig, {Roberto H.} and Pham, {Ha T.} and Perkins, {Sherrie L.} and Prchal, {Josef T.} and Agarwal, {Archana M.} and Mohamed Salama",
year = "2016",
month = "6",
day = "2",
doi = "10.3109/10428194.2015.1091932",
language = "English (US)",
volume = "57",
pages = "1429--1435",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden

AU - Nussenzveig, Roberto H.

AU - Pham, Ha T.

AU - Perkins, Sherrie L.

AU - Prchal, Josef T.

AU - Agarwal, Archana M.

AU - Salama, Mohamed

PY - 2016/6/2

Y1 - 2016/6/2

N2 - The frequency of co-existing JAK2V617F/MPL and JAK2V617F/JAK2 exon-12 mutations has not been previously investigated in MPNs. Poor survival was reported in primary myelofibrosis with low JAK2V617F allelic burden. However, mutational status of JAK2 exon-12 or MPL were not reported in these patients. This study developed a cost-effective multiplex high resolution melt assay that screens for mutations in JAK2 gene exons-12 and -14 (V617F) and MPL gene exon-10. Co-existing mutations with JAK2V617F were detected in 2.9% (6/208; two JAK2 exon-12 and four MPL exon-10) patient specimens with known JAK2V617F (allelic-burden range: 0.1-96.8%). Co-existing mutations were detected in specimens with < 12% JAK2V617F allelic burden. Current WHO guidelines do not recommend further testing once JAK2V617F mutation is detected in MPNs. The findings, however, indicate that quantification of JAK2V617F allele burden may be clinically relevant in MPNs and in those with low allelic burden additional testing for JAK2 exon-12 and MPL exon-10 mutation should be pursued.

AB - The frequency of co-existing JAK2V617F/MPL and JAK2V617F/JAK2 exon-12 mutations has not been previously investigated in MPNs. Poor survival was reported in primary myelofibrosis with low JAK2V617F allelic burden. However, mutational status of JAK2 exon-12 or MPL were not reported in these patients. This study developed a cost-effective multiplex high resolution melt assay that screens for mutations in JAK2 gene exons-12 and -14 (V617F) and MPL gene exon-10. Co-existing mutations with JAK2V617F were detected in 2.9% (6/208; two JAK2 exon-12 and four MPL exon-10) patient specimens with known JAK2V617F (allelic-burden range: 0.1-96.8%). Co-existing mutations were detected in specimens with < 12% JAK2V617F allelic burden. Current WHO guidelines do not recommend further testing once JAK2V617F mutation is detected in MPNs. The findings, however, indicate that quantification of JAK2V617F allele burden may be clinically relevant in MPNs and in those with low allelic burden additional testing for JAK2 exon-12 and MPL exon-10 mutation should be pursued.

KW - allelic burden

KW - Co-existing mutations

KW - myeloproliferative neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84951284468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951284468&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1091932

DO - 10.3109/10428194.2015.1091932

M3 - Article

VL - 57

SP - 1429

EP - 1435

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -